PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Tumor-targeting Salmonella typhimurium A1-R Inhibits Osteosarcoma Angiogenesis in the In Vivo Gelfoam® Assay Visualized by Color-coded Imaging.

Abstract We previously developed a color-coded imaging model that can quantify the length of nascent blood vessels using Gelfoam® implanted in nestin-driven green fluorescent protein (ND-GFP) nude mice. In this model, nascent blood vessels selectively express GFP. We also previously showed that osteosarcoma cells promote angiogenesis in this assay. We have also previously demonstrated the tumor-targeting bacteria Salmonella typhimurium A1-R (S. typhimurium A1-R) can inhibit or regress all tested tumor types in mouse models. The aim of the present study was to determine if S. typhimurium A1-R could inhibit osteosarcoma angiogenesis in the in vivo Gelfoam® color-coded imaging assay.
PMID
Related Publications

Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity.

Color-coded imaging of spontaneous vessel anastomosis in vivo.

A color-coded imaging model of the interaction of αv integrin-GFP expressed in osteosarcoma cells and RFP expressing blood vessels in Gelfoam® vascularized in vivo.

Fluorescent angiogenesis models using gelfoam® implanted in transgenic mice expressing fluorescent proteins.

Osteosarcoma cells enhance angiogenesis visualized by color-coded imaging in the in vivo Gelfoam® assay.

Authors

Mayor MeshTerms

Salmonella typhimurium

Keywords

GFP

Gelfoam®

RFP

Salmonella typhimurium A1-R

angiogenesis

nestin

osteosarcoma

transgenic nude mice

tumor-targeting

Journal Title anticancer research
Publication Year Start




PMID- 29277768
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20180101
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Tumor-targeting Salmonella typhimurium A1-R Inhibits Osteosarcoma Angiogenesis in
      the In Vivo Gelfoam(R) Assay Visualized by Color-coded Imaging.
PG  - 159-164
AB  - BACKGROUND: We previously developed a color-coded imaging model that can quantify
      the length of nascent blood vessels using Gelfoam(R) implanted in nestin-driven
      green fluorescent protein (ND-GFP) nude mice. In this model, nascent blood
      vessels selectively express GFP. We also previously showed that osteosarcoma
      cells promote angiogenesis in this assay. We have also previously demonstrated
      the tumor-targeting bacteria Salmonella typhimurium A1-R (S. typhimurium A1-R)
      can inhibit or regress all tested tumor types in mouse models. The aim of the
      present study was to determine if S. typhimurium A1-R could inhibit osteosarcoma 
      angiogenesis in the in vivo Gelfoam(R) color-coded imaging assay. MATERIALS AND
      METHODS: Gelfoam(R) was implanted subcutaneously in ND-GFP nude mice. Skin flaps 
      were made 7 days after implantation and 143B-RFP human osteosarcoma cells
      expressing red fluorescent protein (RFP) were injected into the implanted
      Gelfoam. After establishment of tumors in the Gelfoam(R), control-group mice were
      treated with phosphate buffered saline via tail-vein injection (iv) and the
      experimental group was treated with S. typhimurium A1-R iv Skin flaps were made
      at day 7, 14, 21, and 28 after implantation of the Gelfoam(R) to allow imaging of
      vascularization in the Gelfoam(R) using a variable-magnification small-animal
      imaging system and confocal fluorescence microscopy. RESULTS: Nascent blood
      vessels expressing ND-GFP extended into the Gelfoam(R) over time in both groups. 
      However, the extent of nascent blood-vessel growth was significantly inhibited by
      S. typhimurium A1-R treatment by day 28. CONCLUSION: The present results indicate
      S. typhimurium A1-R has potential for anti-angiogenic targeted therapy of
      osteosarcoma.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kiyuna, Tasuku
AU  - Kiyuna T
AD  - AntiCancer Inc., San Diego, CA, U.S.A.
AD  - Department of Surgery, University of California, San Diego, CA, U.S.A.
AD  - Department of Orthopedic Surgery, Graduate School of Medicine, University of the 
      Ryukyus, Okinawa, Japan.
FAU - Tome, Yasunori
AU  - Tome Y
AD  - Department of Orthopedic Surgery, Graduate School of Medicine, University of the 
      Ryukyus, Okinawa, Japan [email protected] [email protected]
FAU - Uehara, Fuminari
AU  - Uehara F
AD  - Department of Orthopedic Surgery, Graduate School of Medicine, University of the 
      Ryukyus, Okinawa, Japan.
FAU - Murakami, Takashi
AU  - Murakami T
AD  - AntiCancer Inc., San Diego, CA, U.S.A.
AD  - Department of Surgery, University of California, San Diego, CA, U.S.A.
FAU - Zhang, Yong
AU  - Zhang Y
AD  - AntiCancer Inc., San Diego, CA, U.S.A.
FAU - Zhao, Ming
AU  - Zhao M
AD  - AntiCancer Inc., San Diego, CA, U.S.A.
FAU - Kanaya, Fuminori
AU  - Kanaya F
AD  - Department of Orthopedic Surgery, Graduate School of Medicine, University of the 
      Ryukyus, Okinawa, Japan.
FAU - Hoffman, Robert M
AU  - Hoffman RM
AD  - AntiCancer Inc., San Diego, CA, U.S.A. [email protected] [email protected]
AD  - Department of Surgery, University of California, San Diego, CA, U.S.A.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Animals
MH  - Bone Neoplasms/blood supply/pathology/*therapy
MH  - Cell Line, Tumor
MH  - Female
MH  - Humans
MH  - Mice, Nude
MH  - Mice, Transgenic
MH  - Neovascularization, Pathologic/*therapy
MH  - Osteosarcoma/blood supply/pathology/*therapy
MH  - *Salmonella typhimurium
OTO - NOTNLM
OT  - GFP
OT  - Gelfoam(R)
OT  - RFP
OT  - Salmonella typhimurium A1-R
OT  - angiogenesis
OT  - nestin
OT  - osteosarcoma
OT  - transgenic nude mice
OT  - tumor-targeting
EDAT- 2017/12/27 06:00
MHDA- 2018/01/02 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/12 00:00 [received]
PHST- 2017/11/03 00:00 [revised]
PHST- 2017/11/09 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
AID - 38/1/159 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):159-164.